Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer

被引:43
作者
Bismar, Tarek A. [1 ,2 ,4 ]
Yoshimoto, Maisa [5 ,6 ]
Duan, Qiuli [3 ]
Liu, Shuhong [1 ]
Sircar, Kanishka [7 ]
Squire, Jeremy A. [5 ,6 ]
机构
[1] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada
[2] So Alberta Canc Inst, Calgary, AB, Canada
[3] Tom Baker Canc Clin, Clin Trial Unit, Calgary, AB, Canada
[4] Segal Canc Ctr, Montreal, PQ, Canada
[5] Kingston Gen Hosp, Dept Pathol & Lab Med, Kingston, ON K7L 2V7, Canada
[6] Queens Univ, Kingston, ON, Canada
[7] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
基金
加拿大健康研究院;
关键词
AR amplification; castration resistant prostate cancer; ERG gene rearrangements; molecular subtypes; PTEN deletion; SPINK1; overexpression; TMPRSS2-ERG GENE FUSION; IN-SITU HYBRIDIZATION; ANDROGEN RECEPTOR; GENOMIC DELETION; FISH ANALYSIS; PROGRESSION; EXPRESSION; ABERRATIONS; SHOWS; REARRANGEMENTS;
D O I
10.1111/j.1365-2559.2011.04116.x
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Aims: Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homologue (PTEN) deletions and serine protease inhibitor Kazal type 1 (SPINK1) overexpression were investigated as potential markers for molecularly subtyping prostate cancer (PCA). However, their incidence and co-association in castration-resistant PCA (CRPC) has not been characterized fully. Methods and results: A cohort of 59 CRPC patients was investigated for ERG rearrangements, PTEN deletions and androgen receptor (AR) amplification by fluorescence in-situ hybridization. SPINK1 overexpression was assessed by immunohistochemistry. ERG rearrangements and PTEN deletions were detected in 22 of 53 (41.5%) and 35 of 55 (63.6%) of cases, with 15 of 22 (68.1%) of ERG rearrangements occurring through deletions. SPINK1 overexpression occurred in three of 51 (5.8%) of cases exclusively in non-ERG rearranged and AR amplification was detected in 12 of 49 (24.4%) of cases. Only PTEN deletions showed intrafocal heterogeneity occurring in nine of 35 (25.7%) of cases. PTEN deletions were significantly associated with each of ERG rearrangements occurring by deletions only (P = 0.001), AR amplification (P = 0.002) and SPINK1 overexpression (P = 0.002). None of the SPINK1 overexpressing tumours showed AR amplification (P = 0.005) and all occurred in PTEN deleted foci (P = 0.002). Conclusion: The study supports the heterogeneous nature of CRPC and confirms a significant association between PTEN, ERG, AR and SPINK1. Characterizing combined markers will aid in defining PCA subgroups relevant to prognosis contributing to the design of improved therapeutic approaches for CRPC.
引用
收藏
页码:645 / 652
页数:8
相关论文
共 46 条
[1]
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer [J].
Attard, G. ;
Clark, J. ;
Ambroisine, L. ;
Fisher, G. ;
Kovacs, G. ;
Flohr, P. ;
Berney, D. ;
Foster, C. S. ;
Fletcher, A. ;
Gerald, W. L. ;
Moller, H. ;
Reuter, V. ;
De Bono, J. S. ;
Scardino, P. ;
Cuzick, J. ;
Cooper, C. S. .
ONCOGENE, 2008, 27 (03) :253-263
[2]
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].
Attard, Gerhardt ;
Swermenhuis, Joost F. ;
Olmos, David ;
Reid, Alison H. M. ;
Vickers, Elaine ;
A'Hern, Roger ;
Levink, Rianne ;
Coumans, Frank ;
Moreira, Joana ;
Riisnaes, Ruth ;
Oommen, Nikhil Babu ;
Hawche, George ;
Jameson, Charles ;
Thompson, Emilda ;
Sipkema, Ronald ;
Carden, Craig P. ;
Parker, Christopher ;
Dearnaley, David ;
Kaye, Stan B. ;
Cooper, Colin S. ;
Molina, Arturo ;
Cox, Michael E. ;
Terstappen, Leon W. M. M. ;
de Bono, Johann S. .
CANCER RESEARCH, 2009, 69 (07) :2912-2918
[3]
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer [J].
Bismar, Tarek A. ;
Yoshimoto, Maisa ;
Vollmer, Robin T. ;
Duan, Qiuli ;
Firszt, Matthew ;
Corcos, Jacques ;
Squire, Jeremy A. .
BJU INTERNATIONAL, 2011, 107 (03) :477-485
[4]
The Role of Androgen Receptor Mutations in Prostate Cancer Progression [J].
Brooke, G. N. ;
Bevan, C. L. .
CURRENT GENOMICS, 2009, 10 (01) :18-25
[5]
Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy [J].
Burnstein, KL .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 95 (04) :657-669
[6]
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate [J].
Carver, Brett S. ;
Tran, Jennifer ;
Gopalan, Anuradha ;
Chen, Zhenbang ;
Shaikh, Safa ;
Carracedo, Arkaitz ;
Alimonti, Andrea ;
Nardella, Caterina ;
Varmeh, Shohreh ;
Scardino, Peter T. ;
Cordon-Cardo, Carlos ;
Gerald, William ;
Pandolfi, Pier Paolo .
NATURE GENETICS, 2009, 41 (05) :619-624
[7]
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer [J].
Chmelar, Renee ;
Buchanan, Grant ;
Need, Eleanor F. ;
Tilley, Wayne ;
Greenberg, Norman M. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (04) :719-733
[8]
TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort [J].
Darnel, Andrew D. ;
LaFargue, Christopher J. ;
Vollmer, Robin T. ;
Corcos, Jacques ;
Bismar, Tarek A. .
CANCER BIOLOGY & THERAPY, 2009, 8 (02) :125-130
[9]
TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort [J].
Demichelis, F. ;
Fall, K. ;
Perner, S. ;
Andren, O. ;
Schmidt, F. ;
Setlur, S. R. ;
Hoshida, Y. ;
Mosquera, J-M ;
Pawitan, Y. ;
Lee, C. ;
Adami, H-O ;
Mucci, L. A. ;
Kantoff, P. W. ;
Andersson, S-O ;
Chinnaiyan, A. M. ;
Johansson, J-E ;
Rubin, M. A. .
ONCOGENE, 2007, 26 (31) :4596-4599
[10]
Deocampo N D, 2003, Minerva Endocrinol, V28, P145